Dose limiting toxicity
Showing 1 - 25 of >10,000
Basal Cell Carcinoma Trial in Aventura (Placebo-containing MNA, 25 µg doxorubicin-containing MNA, 50 µg doxorubicin-containing
Terminated
- Basal Cell Carcinoma
- Placebo-containing MNA
- +4 more
-
Aventura, FloridaThe Center for Clinical and Cosmetic Research
Aug 16, 2022
Metastatic Colorectal Cancer Trial in Washington (TF2/IMP288)
Withdrawn
- Metastatic Colorectal Cancer
-
Washington, District of ColumbiaGeorgetown University Medical Center
Aug 12, 2021
Evaluation of High Dose Methotrexate Toxicity
Not yet recruiting
- Methotrexate Toxicity
- blood methotrexate level and Cystatin C level
- (no location specified)
Nov 7, 2023
Resistance Training, Colon Cancer, Chemo Effect Trial in Oakland, Boston, Hershey (Resistance training)
Completed
- Resistance Training
- +2 more
- Resistance training
-
Oakland, California
- +2 more
Jul 27, 2022
Breast Cancer Trial (Reimbursement)
Not yet recruiting
- Breast Cancer
- Reimbursement
- (no location specified)
May 22, 2023
Anal Cancer Trial in Cincinnati (Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c)
Not yet recruiting
- Anal Cancer
- Radiation (reduced elective nodal dose (30.6 Gy)
- +2 more
-
Cincinnati, OhioUniversity of Cincinnati Medical Center
Jun 5, 2023
Prostate Cancer Trial in Québec (Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant, Stereotactic Body
Recruiting
- Prostate Cancer
- Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant
- Stereotactic Body Radiation Therapy to the prostate
-
Québec, CanadaCentre Intégré de Cancérologie, CHU de Québec-Université Laval
Sep 21, 2023
Prostatic Tumors, Castration-Resistant Trial in Brisbane ([212Pb]Pb-ADVC001)
Not yet recruiting
- Prostatic Neoplasms
- Castration-Resistant
-
Brisbane, Queensland, AustraliaRoyal Brisbane & Women's Hospital
Feb 9, 2023
Prostate Cancer, Radiotherapy Side Effect Trial (Brachytherapy, Sterotactic Body Radiotherapy)
Not yet recruiting
- Prostate Cancer
- Radiotherapy Side Effect
- Brachytherapy
- Sterotactic Body Radiotherapy
- (no location specified)
Nov 14, 2022
High Dose Re-Irradiation Utilizing Advanced Deformable Image
Not yet recruiting
- Solid Tumor
- Re-irradiation
- (no location specified)
Jun 13, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte, New York, Houston (BTX-A51)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
-
Duarte, California
- +2 more
Sep 8, 2022
Assessment of Methadone Dose Taken Using Electrochemistry
Not yet recruiting
- Methadone Toxicity
- +4 more
- ISF extraction device 1
- +4 more
- (no location specified)
Aug 7, 2023
EBV-associated Lymphomas Trial ((Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell
Not yet recruiting
- EBV-associated Lymphomas
- (Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate
- (no location specified)
May 31, 2023
Sarcoma Trial in Guangzhou (Fluzoparib+ Dalpiciclib)
Recruiting
- Sarcoma
- Fluzoparib+ Dalpiciclib
-
Guangzhou, Guangdong, ChinaCancer Center of Sun-Yat Sen University (CCSYSU)
Jul 11, 2023
Non-muscle Invasive Bladder Cancer Trial (TARA-002)
Not yet recruiting
- Non-muscle Invasive Bladder Cancer
- TARA-002
- (no location specified)
Aug 24, 2022
Non-muscle Invasive Bladder Cancer Trial in Hanover, Mount Laurel, Rochester (TARA-002)
Recruiting
- Non-muscle Invasive Bladder Cancer
- TARA-002
-
Los Angeles, California
- +11 more
Jan 31, 2023
Cholera, Cholera Vaccine Toxicity Trial in Boston (PanChol)
Recruiting
- Cholera
- Cholera Vaccine Toxicity
- PanChol
-
Boston, MassachusettsBrigham and Women's Hospital Vaccine Unit
Dec 11, 2022
HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)
Active, not recruiting
- HER2-positive Breast Cancer
- Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Jan 30, 2023
EBV-associated Haematologic Tumors Trial ((Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed
Not yet recruiting
- EBV-associated Haematologic Neoplasms
- (Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate
- (no location specified)
Dec 4, 2022
